• 知识
  • 视频
  • 社区
  •  首页
政策法规
  •  国内药监
  •  FDA
  •  EU
  •  PIC/S
  •  WHO
  •  ICH
  •  MHRA
  •  PMDA
  •  TGA
研发注册
  •  概览
  •  监管动态
  •  研究专题
生产质量
  •  概览
  •  监管动态
  •  各国GMP
  •  中国GMP
  •  中国GMP指南
  •  GMP对比
  •  检查缺陷
  •  研究专题
主题词库
  •  主题词库
帮助中心
  •  帮助中心
关于识林
  •  识林介绍
  •  识林FAQs
  •  功能介绍
  •  团队诊断
  •  联系我们
登录
  •  登录
  •  注册
替换
查找内容:
替换为:
全部替换
插入链接
链接网址:
链接显示标题:
请选择网址类型
点我插入链接
插入文件
文件名称:
文件显示标题:
请选择文件类型
点我插入文件
发现错误 发表观点

原文内容

反馈意见

提交 正在提交..... 反馈历史

复制下面的地址分享给好友

确定 正在提交.....
train

你好,

关闭
提交 重做 重新开始 关闭
跳转
  • 新建同级
  • 新建子级
  • 删除
  • 重命名
选择收藏夹
新建收藏夹
公开

取消 确定

1. 基本信息
姓名:
企业:
职位:
联系方式:
邮箱:
2. 请在此填写您的问题,我们将优先安排答疑
提交

报名成功!
课程观看链接如下:
请添加课程助理微信,获得更多信息:
确认
确定

  • 知识
  • 视频
  • 社区
  • 政策法规
    • 国内药监
    • FDA
    • EU
    • PIC/S
    • WHO
    • ICH
    • MHRA
    • PMDA
    • TGA
  • 研发注册
    • 概览
    • 监管动态
    • 研究专题
  • 生产质量
    • 概览
    • 监管动态
    • 各国GMP
    • 中国GMP
    • 中国GMP指南
    • GMP对比
    • 检查缺陷
    • 研究专题
  • 主题词库
  • 帮助中心
  • 关于识林
    • 识林介绍
    • 识林FAQs
    • 功能介绍
    • 团队诊断
    • 联系我们
  • 30天免登录

    忘记密码?

识林

安非他酮缓释片仿制药故事继续

首页 > 资讯 > 安非他酮缓释片仿制药故事继续

页面比对

出自识林

安非他酮缓释片仿制药故事继续
BE
页面比对
笔记

2013-04-01 Lachman CONSULTANTS

跳转到: 导航, 搜索

The Continuing Saga of Generic Bupropion – Is the End Near?
Written by Bob Pollock • April 01, 2013

Bupropion Hydrochloride Extended-Release Tablets 300 mg have been in the news ever since the Office of Generic Drugs (OGD) approved the first generic version for Impax Laboratories on December 15, 2006. That product was the subject of many reports of lack of effect when the switch was made from the innovator's 300 mg product.
(相关阅读:【FDA称TEVA 300mg抗抑郁药与原研药不等效 识林资讯】)

The peculiar issue associated with this product approval relates to the strength upon which the original bioequivalence study was conducted to support approval of the generic products. The innovator product was approved in both a 150 mg and 300 mg strength. However, at the time of generic application submissions, the OGD was worried about the use of a 300 mg dose in normal healthy volunteers due to the potential for first-dose seizures as outlined in the labeling. Because at the time OGD considered this a possible safety issue, they permitted the generic applicants to conduct bioequivalence testing on the 150 mg strength and permitted the firm to “waive” the 300 mg in vivo requirement. (OGD typically requires bioequivalence testing on the highest dose of the approved reference listed drug (RLD) unless there is a potential safety issue with a higher strength.)

The Agency has been addressing the reports of problems with this product for quite a while and, based on a bioequivalence study the FDA commissioned, it was determined that the Impax 300 mg tablet was not bioequivalent to the RLD.

Lachmann.jpg

On October 31, 2012, the law firm of Covington and Burling submitted a Citizen Petition, FDA-2012-P-1091 (here), on behalf of the Valeant Pharmaceuticals (the RLD and NDA holder) requesting that the Agency take certain steps relative to approved and pending generic applications, including 1) withdrawal of the approved generic ANDAs (there were 5 at the time of the issuance of the petition action letter; ;2) require bioequivalence studies to measure the three main metabolites of bupropion and apply a 90% confidence interval to each metabolite; 3) require Tmax as a bioequivalence metric; 4) require generic firms to conduct a pharmacovigilance analysis on any lack of effect complaints on their product; and finally 5) they requested that the Agency convene a public advisory committee on the issues.

The Petition was granted in part and denied in part. The FDA outlined its reasoning relative to the already approved products (described in detail below) and refused to take regulatory action against the products until the results of the requested bioequivalence studies are conducted, indicating that they have a high degree of confidence in the other approved 300 mg generic products.

"We agree that the four generic 300 mg bupropion HCl ER products remaining on the market were approved using the same bioequivalence standards as Budeprion XL and were originally granted waivers of in vivo BE testing on the 300 mg strength. However, FDA has asked these sponsors (Anchen, Actavis, Watson, and Mylan) to conduct additional studies to confirm the bioequivalence of their 300 mg bupropion HCl ER tablets, and to submit the results to FDA. The Agency also believes that the bioequivalence issues with the Impax/Teva 300 mg product may have been the result of that product's particular formulation and thus limited to that product. We expect that the additional bioequivalence studies that we have asked Anchen, Actavis, Watson, and Mylan to perform will be sufficient to determine whether each of those products is bioequivalent to Wellbutrin XL 300 mg. Based on the information available to us, we do not believe it is necessary to withdraw approval of these products prior to completing our review of the results of the confirmatory BE studies. Once our review of the study data is complete, FDA will take any appropriate regulatory action."

FDA did agree that it was important to measure and evaluate the three major metabolites of bupropion and report those values; however, only the parent compound, bupropion, would be subject to the confidence interval approach.

In addition, FDA denied the firm's request to apply Tmax as a bioequivalence criteria and noted that the product is a chronically administered medication and the impact of Tmax, even if there were a difference of several hours, is not considered meaningful to efficacy.

Further, FDA denied a request for additional analysis of lack of effect reports as manufacturers of the specific products are often not identified. FDA did note that firms are responsible to report these events, and thus, the Agency would have the required information available to it. FDA also denied the petitioner's request to convene a public advisory committee to discuss the issues.

While some have pointed to this incident in an attempt to question the generic drug review and approval process, there are very few examples of generic products that have been withdrawn for bioequivalence issues after approval. As a matter of fact, I can think of only three since the approval of the Hatch-Waxman Amendments in 1984. Considering that OGD approves an average of about 450 ANDAs a year, and with generics accounting for 80% of all prescriptions dispensed, that is a pretty stellar record.

原文请见 The Continuing Saga of Generic Bupropion – Is the End Near?

取自“https://lib.shilinx.com/wiki/index.php?title=%E5%AE%89%E9%9D%9E%E4%BB%96%E9%85%AE%E7%BC%93%E9%87%8A%E7%89%87%E4%BB%BF%E5%88%B6%E8%8D%AF%E6%95%85%E4%BA%8B%E7%BB%A7%E7%BB%AD”
上一页: 2012版GSP验证管理等附录征求意见
下一页: CFDA主要职责内设机构和人员编制规定
相关内容
相关新闻
  • FDA将加强对缓控释药品的审查
  • FDA悄然撤销第二例安非他酮仿...
  • FDA称TEVA 300mg抗抑郁药与原...
  • FDA对异丙酚注射剂的新BE要求
  • FDA否定请愿并修订鲁比前列酮B...
热点新闻
  • ICH 发布新 Q1 稳定性指南...
  • 学习 “药典文献汇编” 迎接...
  • 【直播】25年4月全球法规月报...
  • 国内无菌附录征求意见稿发布,...
  • 国内药政每周导读:工艺验证检...

 反馈意见

Copyright ©2011-2025 shilinx.com All Rights Reserved.
识林网站版权所有 京ICP备12018650号-2 (京)网药械信息备字(2022)第00078号
请登录APP查看
打开APP